New checkpoint blockers begin human trials - PubMed (original) (raw)

New checkpoint blockers begin human trials

Ken Garber. J Natl Cancer Inst. 2005.

No abstract available

PubMed Disclaimer

Similar articles

• New drugs target hypoxia response in tumors.
  Garber K. Garber K. J Natl Cancer Inst. 2005 Aug 3;97(15):1112-4. doi: 10.1093/jnci/dji261. J Natl Cancer Inst. 2005. PMID: 16077066 No abstract available.
• Epothilone D (Kosan/Roche).
  Kolman A. Kolman A. Curr Opin Investig Drugs. 2004 Jun;5(6):657-67. Curr Opin Investig Drugs. 2004. PMID: 15242255 Review.
• OSI-461 (OSI).
  Galmarini CM. Galmarini CM. Curr Opin Investig Drugs. 2004 Jun;5(6):648-56. Curr Opin Investig Drugs. 2004. PMID: 15242254 Review.
• [In vitro inhibitory effect of dibenzoxanthene CY-B12 on proliferation of tumor cell lines and its possible mechanisms].
  Pu XX, Jiang GF, Chen Y, Xu ZL, Xian LJ. Pu XX, et al. Ai Zheng. 2005 Dec;24(12):1442-7. Ai Zheng. 2005. PMID: 16351789 Chinese.
• DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
  Skladanowski A, Bozko P, Sabisz M. Skladanowski A, et al. Chem Rev. 2009 Jul;109(7):2951-73. doi: 10.1021/cr900026u. Chem Rev. 2009. PMID: 19522503 Review. No abstract available.

Cited by

• Camptothecin induces G2/M phase arrest through the ATM-Chk2-Cdc25C axis as a result of autophagy-induced cytoprotection: Implications of reactive oxygen species.
  Prasad Tharanga Jayasooriya RG, Dilshara MG, Neelaka Molagoda IM, Park C, Park SR, Lee S, Choi YH, Kim GY. Prasad Tharanga Jayasooriya RG, et al. Oncotarget. 2018 Apr 24;9(31):21744-21757. doi: 10.18632/oncotarget.24934. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774099 Free PMC article.
• Targeting DNA repair and the cell cycle in glioblastoma.
  Alexander BM, Pinnell N, Wen PY, D'Andrea A. Alexander BM, et al. J Neurooncol. 2012 May;107(3):463-77. doi: 10.1007/s11060-011-0765-4. Epub 2011 Nov 24. J Neurooncol. 2012. PMID: 22113697 Review.
• Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
  Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ. Peasland A, et al. Br J Cancer. 2011 Jul 26;105(3):372-81. doi: 10.1038/bjc.2011.243. Epub 2011 Jul 5. Br J Cancer. 2011. PMID: 21730979 Free PMC article.
• Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
  Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S. Azorsa DO, et al. J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43. J Transl Med. 2009. PMID: 19519883 Free PMC article.
• Regulation of Chk1 by its C-terminal domain.
  Kosoy A, O'Connell MJ. Kosoy A, et al. Mol Biol Cell. 2008 Nov;19(11):4546-53. doi: 10.1091/mbc.e08-04-0444. Epub 2008 Aug 20. Mol Biol Cell. 2008. PMID: 18716058 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program